Reintroduction Phase — Food Challenges After an Elimination Diet

Table of Contents

1. Why Reintroduction Matters in the Research
2. How Food Challenges Are Structured
3. Timing of Reactions in Challenge Protocols
4. How Symptoms Are Recorded
5. Interpretation — What Counts as a Positive Challenge
6. Placebo and Nocebo Effects in Blinded Challenges
7. Changing Tolerance Over Time
8. Outcomes — Exclusion, Limited Intake or Full Return
9. Reintroduction in Specific Diets and Conditions
10. Where Studies Describe Specialist Involvement
11. Key Research Papers
12. Connections
13. Featured Videos

Why Reintroduction Matters in the Research

The published reasons for reintroducing foods, rather than staying on the full elimination diet, fall into three groups:

• Symptom control can be kept with a broader diet. The Monash review states that patients are encouraged not to remain on a strict low-FODMAP diet long-term and that many keep their symptom improvement with a relaxed, moderate FODMAP restriction (Tuck 2017). In a randomized trial of 50 people with IBS in New Zealand, the improvement in symptom scores seen after three months of a low-FODMAP diet was sustained at six months in the group that had gone on to re-challenge foods (Harvie 2017, PubMed PMID: 28740352).
• Nutrition recovers. In the same trial, fiber intake fell from 33 to 21 g a day on the low-FODMAP diet and rose again to 27 g a day after FODMAP-containing foods were reintroduced; the authors found no change in the intestinal microbiome when participants adopted the low-FODMAP diet (Harvie 2017).
• Most people turn out to have only a few triggers. In an adult eosinophilic esophagitis (EoE) study using a six-food elimination diet, sequential single-food reintroduction identified one trigger food in 35.71% of patients, two in 30.95% and three or more in 33.3% (Lucendo 2013, PubMed PMID: 23375693). In the multicentre 2-4-6 study, 55 of 60 responders (91.6%) to the two- or four-food-group diets had one or two food triggers, and the authors describe the step-up approach as avoiding unnecessary dietary restrictions (Molina-Infante 2018, PubMed PMID: 29074457).

A Monash review aimed at gastroenterologists adds that the nutritional and psychological risks of the diet must be mitigated, and lists among its key recommendations screening for eating-disorder risk and avoiding labelling foods as "good" or "bad," "safe" or "unsafe," because such language can contribute to food-related fear, guilt or shame (Sultan 2022, PubMed PMID: 35799231).

Back to Table of Contents

How Food Challenges Are Structured

The structure of a challenge differs by condition. What the studies and practice papers describe:

• FODMAPs in IBS: in the New Zealand trial, participants were taught to reintroduce FODMAP molecules individually and systematically, with dietitian follow-up (Harvie 2017). The Monash review states that the challenge process is tailored to the individual patient, that well-tolerated FODMAP subgroups allow some moderate- to high-FODMAP foods back without symptoms, and that less well-tolerated subtypes may also be reintroduced with an individualised dose and frequency (Tuck 2017). For foods of unknown FODMAP content, the 2022 review describes a "test to tolerance" approach: once symptoms are well controlled, a small amount (about one-third of a usual serving) is included daily for 3 days (Sultan 2022).
• Eosinophilic esophagitis: in the 2-4-6 study, patients first spent 6 weeks on a two-food-group elimination diet (milk and gluten-containing cereals); non-responders were stepped up to four and then six food groups, and in responders each eliminated food group was reintroduced individually, followed by endoscopy (Molina-Infante 2018). In the adult six-food study, the diet excluded cereals, milk, eggs, fish/seafood, legumes/peanuts and soy for 6 weeks; excluded single foods were then reintroduced sequentially, with endoscopy and biopsies every 6 weeks (Lucendo 2013).
• Suspected food allergy: an American Academy of Allergy, Asthma & Immunology work group describes oral food challenges as procedures conducted by allergists/immunologists. The timing is chosen from the patient's history and skin prick and food-specific IgE results; the type of challenge from the history, the patient's age and the likelihood of subjective reactions; and the starting dose, dose escalation and intervals from experience and the patient's history. The office is prepared in advance for assessing symptoms and treating reactions (Nowak-Wegrzyn 2009, PubMed PMID: 19500710). The 2024 AAAAI–EAACI PRACTALL update, which revises the 2012 PRACTALL consensus report (Sampson 2012, PubMed PMID: 23195525), describes semi-logarithmic incremental doses based on protein content, typically with 20–30 minutes between doses for IgE-mediated food allergy (Sampson 2024, PubMed PMID: 39560049).
• Suspected non-celiac gluten sensitivity: the Salerno experts' criteria describe a double-blind, placebo-controlled gluten challenge of 8 g a day: a one-week challenge, a one-week washout on a strict gluten-free diet, then crossover to a second one-week challenge. The vehicle contains cooked, homogeneously distributed gluten (Catassi 2015, PubMed PMID: 26096570).

No published study has tested a reintroduction method after a carnivore diet; the Carnivore Reset page reports what the case series describe.

Back to Table of Contents

Timing of Reactions in Challenge Protocols

Challenge protocols are built around how quickly a given kind of reaction appears:

• Immediate reactions: the AAAAI work group describes oral food challenges as a way to diagnose immediate, and occasionally delayed, adverse reactions to foods (Nowak-Wegrzyn 2009). For IgE-mediated allergy, PRACTALL describes doses given 20–30 minutes apart, with stopping criteria ("go on," "stop" or "observation") intended to reduce both false-positive diagnoses and severe reactions; it details separate protocols for other reaction types, such as atopic dermatitis and gastrointestinal food allergy (Sampson 2024).
• Days to a week: gluten challenges in suspected gluten sensitivity run for one week (Catassi 2015); in the Biesiekierski trial, the challenge diets lasted 1 week, and a later rechallenge lasted 3 days (Biesiekierski 2013, PubMed PMID: 23648697). The FODMAP "test to tolerance" approach runs over 3 days (Sultan 2022).
• Weeks, judged by biopsy: in EoE, a reintroduced food was judged by esophageal biopsy after each 6-week step, not by symptoms alone (Lucendo 2013).

The timescales differ by condition, and the studies above do not set one observation window for every elimination diet.

Back to Table of Contents

How Symptoms Are Recorded

The studies record symptoms on structured scales rather than from memory:

• Salerno criteria: a self-administered instrument based on a modified Gastrointestinal Symptom Rating Scale; the patient names one to three main symptoms, each scored on a 1–10 numerical rating scale (Catassi 2015).
• IBS trials: the IBS Symptom Severity Score (0–500 points, higher meaning more severe) and an IBS quality-of-life questionnaire, alongside a FODMAP-specific food frequency questionnaire (Harvie 2017).
• Allergy-focused diet history: a European Academy of Allergy and Clinical Immunology task force developed paediatric and adult diet-history tools with traffic-light stages: red (gathering symptoms, atopic history, suspected food triggers, foods eaten and nutritional issues), amber (interpreting the answers) and green (a summary template and test algorithm). The authors note that published evidence on the allergy-focused history is sparse and that the tools still need validation (Skypala 2015, PubMed PMID: 25741437).

On self-guided approaches, the 2022 Monash review states that delivery through technology or specialised food services may be an alternative where dietitians are not available, but that efficacy data are limited (Sultan 2022).

Back to Table of Contents

Interpretation — What Counts as a Positive Challenge

Each field defines a positive result in its own terms:

• Gluten sensitivity: at least a 30% variation in one to three main symptoms between the gluten and the placebo challenge (Catassi 2015).
• Eosinophilic esophagitis: a food was considered a trigger, and removed from the diet, if 15 or more eosinophils per high-power field reappeared on biopsy (Lucendo 2013); remission in the 2-4-6 study was defined as symptom improvement plus fewer than 15 eosinophils per high-power field (Molina-Infante 2018). In a retrospective series of 941 children with EoE at one US children's hospital, a food was considered causative if eliminating it led to resolution of esophageal eosinophilia or reintroducing it led to recurrence (Spergel 2012, PubMed PMID: 22743304).
• Food allergy: the AAAAI work group states that a negative oral food challenge allows the food to be introduced into the diet, while a positive result provides a sound basis for continued avoidance (Nowak-Wegrzyn 2009).

Allergy tests do not replace the challenge itself. In the adult EoE study, prior allergy tests showed no concordance with the food-reintroduction results (Lucendo 2013). In the paediatric series, the combination of skin prick and atopy patch tests had an average negative predictive value of 92% (44% for milk) and an average positive predictive value of 44% (Spergel 2012). Testing for food-specific IgG4 is described by a European Academy of Allergy and Clinical Immunology task force as a marker of repeated exposure and immunological tolerance, not of allergy or intolerance, and as irrelevant to the laboratory work-up of food allergy or intolerance (Stapel 2008, PubMed PMID: 18489614). A 2018 review of food IgG or IgG4 antibodies, white-cell volume testing, provocation-neutralization, hair analysis, electrodermal testing and applied kinesiology reports that blinded, controlled studies of some of these tests showed a lack of reproducibility and of correlation with disease, and that most lack biological plausibility (Kelso 2018, PubMed PMID: 29524991).

Back to Table of Contents

Placebo and Nocebo Effects in Blinded Challenges

Blinded, placebo-controlled challenges have shown that expectation can produce symptoms on its own:

• Biesiekierski 2013: a double-blind crossover trial of 37 people with self-reported non-celiac gluten sensitivity and IBS (not celiac disease). Gastrointestinal symptoms improved on two weeks of reduced FODMAP intake, then worsened to a similar degree when the diet included gluten or whey protein (the control). Gluten-specific effects were seen in only 8% of participants, there were no diet-specific changes in any biomarker, gluten-specific effects were not reproduced on a 3-day rechallenge, and an order effect was observed (Biesiekierski 2013).
• Molina-Infante and Carroccio 2017: an analysis of 10 double-blind, placebo-controlled gluten-challenge trials (1,312 adults) found that only 38 of 231 patients with suspected gluten sensitivity (16%) showed gluten-specific symptoms, and that 40% of these had a nocebo response, with similar or greater symptoms on placebo (PubMed PMID: 27523634).
• Seiler 2025: in a randomized, double-blind, sham-controlled crossover trial in 28 adults with IBS who believed a gluten-free diet had helped them, symptoms worsened by at least 50 points after wheat in 39%, after gluten in 36% and after a sham bar in 29%, with no statistically significant differences. The authors conclude that expectations played a major role in symptom generation and that only some of these patients could benefit from gluten or wheat restriction (PubMed PMID: 40706614).
• Iven 2025: a randomized, single-blind crossover study in 16 people with non-celiac gluten sensitivity and 20 healthy controls found more fatigue and gastrointestinal symptoms in the gluten-sensitive group that were not gluten-specific, which the authors say may be explained by nocebo effects (PubMed PMID: 40138597).

The methods these studies used to separate a food's effect from expectation: test and placebo vehicles matched for appearance, taste and smell (Seiler 2025); cooked gluten distributed evenly through the vehicle (Catassi 2015); placebo-controlled crossover with washout periods (Catassi 2015; Biesiekierski 2013); and, in EoE, an objective endpoint — the biopsy eosinophil count (Lucendo 2013).

Back to Table of Contents

Changing Tolerance Over Time

Tolerance found on a challenge is not necessarily fixed. The 2022 Monash review describes encouraging patients to reintroduce poorly tolerated high-FODMAP foods periodically to re-assess tolerance, because tolerance may change over time (Sultan 2022).

For lactose, a single-patient case report describes a man whose hydrogen breath test was negative on a 50 g lactose challenge while he was eating about 28.1 g of lactose a day. When his lactose intake was sharply reduced, a full lactase non-persistent status was unmasked, and breath-hydrogen output varied inversely with his daily lactose intake across further tests over the next 10 months. The authors attribute this to adaptation of the colonic bacteria, and found no cross-adaptation to lactulose (Szilagyi 2004, PubMed PMID: 15565208). It is one case, and it does not show how often this happens after an elimination diet.

Back to Table of Contents

Outcomes — Exclusion, Limited Intake or Full Return

The studies describe three kinds of result for a reintroduced food:

• Continued exclusion: in EoE, foods that brought back eosinophilic inflammation were removed. All patients in the adult six-food study who kept avoiding their trigger foods stayed in histological and clinical remission for up to 3 years, on what the authors call individually tailored, limited exclusion diets (Lucendo 2013). In food allergy, a positive oral food challenge is described as a sound basis for continued avoidance (Nowak-Wegrzyn 2009).
• Limited intake: in the low-FODMAP diet, less well-tolerated subtypes may be reintroduced with an individualised dose and frequency, and the review describes the goal as a balance between good symptom control and expansion of the diet (Tuck 2017).
• Full return: well-tolerated FODMAP subgroups allow some moderate- to high-FODMAP foods back into the diet without symptoms (Tuck 2017), and a negative oral food challenge allows the food into the diet (Nowak-Wegrzyn 2009).

The King's College review describes the end point of the low-FODMAP diet as personalisation: a less restrictive diet that excludes the person's own FODMAP triggers and allows a more diverse intake (Whelan 2018).

Back to Table of Contents

Reintroduction in Specific Diets and Conditions

• Low-FODMAP diet: there is published practice guidance (Tuck 2017; Whelan 2018; Sultan 2022) and a randomized trial that followed patients through reintroduction (Harvie 2017). The Monash review still states that limited evidence is available to guide best practice (Tuck 2017).
• Autoimmune protocol (AIP) diet: in an uncontrolled study of 15 adults with active inflammatory bowel disease, a 6-week elimination followed by a 5-week maintenance phase was followed by significant improvements in ulcerative colitis and Crohn's disease activity scores; C-reactive protein did not change significantly, and the authors call for randomized trials (Konijeti 2017, PubMed PMID: 28858071). The abstract does not report how foods were reintroduced.
• Whole30: a PubMed search for "Whole30" returned no indexed studies (October 2026), and no study of the program's reintroduction sequence was found; see the Whole30 page.
• Carnivore diet: no published study has tested a reintroduction method; see the Carnivore Reset page.
• Eosinophilic esophagitis: the 2-4-6 step-up study found remission in 43% of children and adults on the two-food-group diet (milk and gluten-containing cereals), and in 60% and 79% on the four- and six-food-group diets. Triggers among two-food-group responders were milk (52%), gluten-containing grains (16%) or both (28%). Compared with starting on a six-food diet, the step-up strategy reduced endoscopic procedures and diagnostic time by 20% (Molina-Infante 2018). In the paediatric series, milk, egg, wheat and soy were the most common causative foods in 319 patients (Spergel 2012).
• Children with suspected food allergy: the AAAAI work group describes oral food challenges as procedures conducted by allergists/immunologists, with the type of challenge chosen partly by the patient's age and the office prepared to treat reactions (Nowak-Wegrzyn 2009); PRACTALL treats the safety of food challenges as paramount (Sampson 2024). In the series of children with EoE, IgE-mediated reactions (urticaria and anaphylaxis) were seen in 15% (Spergel 2012).

Back to Table of Contents

Where Studies Describe Specialist Involvement

The papers above describe several situations in which reintroduction is supervised:

• Suspected IgE-mediated food allergy: oral food challenges are described as procedures conducted by allergists/immunologists, in an office prepared to treat reactions (Nowak-Wegrzyn 2009; Sampson 2024).
• Eosinophilic esophagitis: each reintroduction step is judged by endoscopy and biopsy (Lucendo 2013; Molina-Infante 2018).
• FODMAP reintroduction: the New Zealand trial authors say their findings highlight the need for the diet to be supervised by an experienced dietitian, especially during the re-challenge phase (Harvie 2017). The 2022 Monash review lists, as situations for dietitian referral, patients who are stuck in the restriction stage and have not challenged or reintroduced foods (especially when self-managing); patients on several restrictive diets at once, such as FODMAP plus gluten-free or vegetarian; patients at risk of or with malnutrition (5% weight loss in 1 month or 10% in 6 months); patients with disordered eating behaviours; and patients with chronic conditions, such as diabetes, that need medical nutritional management (Sultan 2022).

Back to Table of Contents

Key Research Papers

1. Tuck C, Barrett J. (2017). Re-challenging FODMAPs: the low FODMAP diet phase two. Journal of Gastroenterology and Hepatology 32 Suppl 1:11–15 — PubMed PMID: 28244664
2. Whelan K et al. (2018). The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. Journal of Human Nutrition and Dietetics — PubMed PMID: 29336079
3. Sultan N et al. (2022). How to Implement the 3-Phase FODMAP Diet Into Gastroenterological Practice. Journal of Neurogastroenterology and Motility 28(3):343–356 — PubMed PMID: 35799231
4. Harvie RM et al. (2017). Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. World Journal of Gastroenterology 23(25):4632–4643 — PubMed PMID: 28740352
5. Nowak-Wegrzyn A et al. (2009). Work Group report: oral food challenge testing. Journal of Allergy and Clinical Immunology — PubMed PMID: 19500710
6. Sampson HA et al. (2012). Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology — European Academy of Allergy and Clinical Immunology PRACTALL consensus report. Journal of Allergy and Clinical Immunology 130(6):1260–1274 — PubMed PMID: 23195525
7. Sampson HA et al. (2024). AAAAI-EAACI PRACTALL: Standardizing oral food challenges — 2024 Update. Pediatric Allergy and Immunology 35(11):e14276 — PubMed PMID: 39560049
8. Biesiekierski JR et al. (2013). No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology — PubMed PMID: 23648697
9. Molina-Infante J, Carroccio A. (2017). Suspected Nonceliac Gluten Sensitivity Confirmed in Few Patients After Gluten Challenge in Double-Blind, Placebo-Controlled Trials. Clinical Gastroenterology and Hepatology 15(3):339–348 — PubMed PMID: 27523634
10. Seiler CL et al. (2025). Effect of gluten and wheat on symptoms and behaviours in adults with irritable bowel syndrome: a single-centre, randomised, double-blind, sham-controlled crossover trial. Lancet Gastroenterology & Hepatology 10(9):794–805 — PubMed PMID: 40706614
11. Iven J et al. (2025). Impact of Acute and Sub-Acute Gluten Exposure on Gastrointestinal Symptoms and Psychological Responses in Non-Coeliac Gluten Sensitivity: A Randomised Crossover Study. United European Gastroenterology Journal 13(7):1295–1306 — PubMed PMID: 40138597
12. Catassi C et al. (2015). Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts' Criteria. Nutrients — PubMed PMID: 26096570
13. Molina-Infante J et al. (2018). Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study. Journal of Allergy and Clinical Immunology — PubMed PMID: 29074457
14. Lucendo AJ et al. (2013). Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis. Journal of Allergy and Clinical Immunology — PubMed PMID: 23375693
15. Spergel JM et al. (2012). Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. Journal of Allergy and Clinical Immunology 130(2):461–467 — PubMed PMID: 22743304
16. Konijeti GG et al. (2017). Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease. Inflammatory Bowel Diseases 23(11):2054–2060 — PubMed PMID: 28858071
17. Szilagyi A et al. (2004). Deadaption and readaptation with lactose, but no cross-adaptation to lactulose: a case of occult colonic bacterial adaptation. Canadian Journal of Gastroenterology 18(11):677–680 — PubMed PMID: 15565208
18. Skypala IJ et al. (2015). The development of a standardised diet history tool to support the diagnosis of food allergy. Clinical and Translational Allergy 5:7 — PubMed PMID: 25741437
19. Kelso JM (2018). Unproven Diagnostic Tests for Adverse Reactions to Foods. Journal of Allergy and Clinical Immunology: In Practice 6(2):362–365 — PubMed PMID: 29524991
20. Carr S et al. (2012). CSACI Position statement on the testing of food-specific IgG. Allergy, Asthma & Clinical Immunology 8(1):12 — PubMed PMID: 22835332
21. Stapel SO et al. (2008). Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy 63(7):793–796 — PubMed PMID: 18489614

PubMed Topic Searches

1. PubMed: FODMAP reintroduction methodology
2. PubMed: Double-blind oral food challenge
3. PubMed: Nocebo effect in gluten sensitivity
4. PubMed: Elimination diet reintroduction
5. PubMed: IgG food testing position statements

Back to Table of Contents

Connections

• All Remedies
• Elimination Diet (Main Hub)
• Benefits Deep-Dive Hub
• Whole30
• Low FODMAP
• Carnivore Reset
• Food
• Irritable Bowel Syndrome
• SIBO
• Celiac Disease
• Crohn's Disease
• Eczema
• Migraine
• Lab Tests
• Immune Boosting

Back to Table of Contents

Featured Videos